Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BW-41012 SAD Study in Healthy Participants
NCT07584876Phase 1Recruiting
- Sponsor
- Shanghai Argo Biopharmaceutical Co., Ltd.
- Start
- May 2026
- Primary completion
- Oct 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BW-41012 in thrombosis (5 cohorts), sponsored by Shanghai Argo Biopharmaceutical Co., Ltd. Primary endpoint: Primary Endpoints (Safety, Tolerability, PK, PD) at 24 hours. Started May 2026; status: recruiting.
02
Drugs
BW-41012
03
Conditions
thrombosis
Beyond the preview
Go deeper on NCT07584876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07584876.